The innovative NV-387 targets viral infections like COVID-19, RSV, and influenza, addressing a $2.5–$4.3 billion market. Acting as a decoy, it traps and neutralizes viruses before they replicate. Successfully completing Phase 1 trials, NV-387 could redefine how we combat viral diseases.

Know more: https://tinyurl.com/58b8wyjc